French biotechnology company Nosopharm has raised €2.4m in funding with Auriga Partners, Kreaxi and Alto Invest to accelerate the regulatory preclinical development of its first antibiotic molecule, NOSO-95179.
The molecule targets Enterobacteriaceae, which is a priority pathogen according to the WHO.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company expects to begin first-in-human studies in 2019.
Nosopharm president Philippe Villain-Guillot said: “Thanks to this, we now have the funds needed to finalise the preclinical programme for NOSO-95179 and launch additional R&D programmes for anti-infective drugs.
“We will submit IND or IMPD applications for NOSO-95179 in 2018, with a view to first-in-man studies in 2019. By the end of 2018 we will also submit new patent applications covering new therapeutic classes of anti-infectives.”
Nosopharm also plans to launch other upstream research programmes in the field of infectious diseases using its new anti-infective biotechnology platform that is based on the medicinal mining of an original microbial bioresource.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAuriga Partners Auriga IV Bioseeds fund partner and manager Franck Lescure said: “The discovery platform for new families of anti-infective agents used by Nosopharm comes from a productive collaboration between the company and the French National Institute for Agricultural Research (INRA).”
NOSO-95179 was discovered consecutively to the lead optimisation of NOSO-95, the first molecule in the new class of Odilorhabdin antibiotics.
It inhibits bacterial translation with a new mode of action and its target indication is to treat polymyxin and carbapenem-resistant Enterobacteriaceae (CRE) infections.
The molecule shows clear in vitro antibacterial activity against multi-drug resistant clinical isolates, along with in vivo efficacy in different murine infection models.
